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We explored the therapeutic eﬀect of NCX 1000, a derivative of ursodeoxycholic acid (UDCA) with nitric oxide (NO) donating
properties, alone or in combination with vitamin E, in an experimental model of NASH in the rat. Methods. A control group was
fed a standard liquid diet (Control), and the NASH groups were fed a high-fat liquid diet for 12 weeks without (NASH) or with
simultaneous daily gavage with either NCX 1000 at 15 or 30mg/kg (N15 and N30, resp.),or N15 plus vitamin E 100mg/kg (N15 +
VitE) for the last 6 weeks; UDCA 17.2mg/kg was used as a reference. Results. NASH rats developed all key features of the disease.
Treatments with N30 improved liver histology, decreased lipid peroxidation, and completely suppressed increases in LDH release,
plasmainsulin,andTNF-α.ItalsodecreasedO 2
•− releaseandreturnedliverweightandglutathionebacktonormal.Alleﬀectswere
similar to the reference treatment, UDCA. The N15 treatment was less eﬃcient than the N30 group, but became comparable to the
latter when combined to vitamin E. Conclusion. Our study demonstrates that NCX 1000 has potent cytoprotective, antioxidant,
and hypoinsulinemic properties that can be enhanced by combination with vitamin E.
1.Introduction
Nonalcoholic steatohepatitis (NASH) was characterized for
the ﬁrst time by Ludwig and colleagues in 1980 [1] as the
inﬂammatory stage following reversible steatosis in the liver.
It is part of the nonalcoholic fatty liver disease (NAFLD)
spectrum, which is now the most common cause of hepatic
illness. NASH is more likely to develop in sedentary inactive
people, following high-fat/high-caloric diets, notably in pos-
sible association with visceral adiposity. It is strongly related
to the metabolic syndrome, being its hepatic expression, and
to type II diabetes mellitus [2–5]. Although the pathogenesis
of NASH is not entirely elucidated, it is now well established
that it involves a multiple-hit process [6]. This includes
insulin resistance and oxidative stress and underlies the
developmentofmacrovesicularsteatosis,necroinﬂammatory
lesions, Mallory body formation, hepatocyte ballooning,
and collagen deposition [7–10]. Furthermore, elevated
inﬂammatory cytokines, elevated or decreased adipokines,
increased lipid peroxidation products, and increased reactive
oxygenspeciesplayamajorroleinthepathogenesisofNASH
[6, 11] .S e v e r a lr e m e d i e sw e r ei n v e s t i g a t e df o rt h et r e a t m e n t
of NASH but an eﬃcient therapy has yet to be developed.
Ursodeoxycholic acid (UDCA) is a hydrophilic biliary
acid known to possess antioxidant properties [12–14]. Its
cytoprotective, antiapoptotic, and membrane stabilizing and
immunomodulative eﬀects have also been acknowledged by
Angulo [15]. It is presently approved for the management
of primary biliary cirrhosis and other cholestatic and nonc-
holestatic liver diseases [16–18]. Several clinical studies have
shown that treating NASH patients with UDCA improved
aminotransferase levels [19–21], adiponectin levels [19], and2 International Journal of Hepatology
grade of steatosis [20, 22]. UDCA was also found eﬀective
in enhancing the therapeutic eﬀects of low caloric diet to
prevent fat-induced NASH in the rat [23]. However, its eﬃ-
ciencywas challengedwhenit failed toshow improvement in
transaminase levels and in steatosis beyond that found in the
placebo group in a doubled-blind random controlled study
[24].
NCX 1000 is a derivative of UDCA with nitric oxide
(NO) donating activity that was reported to be eﬃcacious in
animal models of liver injury due to its immunomodulatory,
cytoprotective and antiapoptotic properties [25–30]. Results
from our previous study show that NCX 1000 exerts a
better protective eﬀect than UDCA on mouse hepatocytes
treated with amiodarone to produce NASH-like lesions in
vitro [31]. Moreover, additive protection was observed with
a combination of NCX 1000 and lipophilic antioxidants such
as vitamin E. However, no animal or clinical studies have yet
assessed the potential beneﬁt of NCX 1000 for the treatment
of NASH.
Thus, based on the previous encouraging in vitro results,
we tested the beneﬁcial eﬀects of NCX 1000 in an experi-
mental model of NASH in the rat and used UDCA at an
equimolar high dose as comparator. We also assessed the
eﬀectofcombiningalowerdoseofNCX1000withvitaminE
andevaluatedtheimpactofalltreatmentsonoxidativestress,
inﬂammation, and the metabolic syndrome parameters.
2.MaterialsandMethods
2.1. Chemicals. All chemicals were purchased from Sigma-
Aldrich (Oakville, ON, Canada). UDCA and NCX 1000 were
graciously provided by Axcan Pharma Inc. (Mont-St-Hilaire,
QC, Canada).
2.2. Animals and Experimental Protocol. Male Sprague-
Dawley rats (75–100g) were purchased from Charles River
Canada (St-Constant, QC, Canada). They had access to nor-
mal rat chow diet and water for 5 days before the beginning
ofexperimentalprotocols.Theywerethenrandomlydouble-
housed and divided into 2 groups of 6 rats and 4 groups
of 10 rats. The control group (Control, n = 6) was fed the
Lieber-DeCarli standard liquid diet (Dyets Inc., Bethlehem,
PA) for 12 weeks. The nonalcoholic steatohepatitis group
(NASH, n = 6) received the Lieber-DeCarli high-fat liquid
diet (Dyets Inc., Bethlehem, PA) for 12 weeks. The treatment
groups (n = 10, each) were fed the same high-fat liquid diet
for 12 weeks to which was added the following respective
treatments during the last 6 weeks; NCX 1000 30mg/kg
(N30), NCX 1000 15mg/kg (N15), NCX 1000 15mg/kg
combined with vitamin E 100mg/kg (N15+VitE), and the
reference treatment group UDCA 17.2mg/kg (UDCA), daily
by intragastric gavage in a 0.5% methylcellulose solution.
The UDCA dose of 17.2mg/kg corresponds to the upper
normal therapeutic range for that drug in clinical studies. In
term of UDCA content, it is equivalent to that of 30mg/kg
of NCX 1000. Diets were prepared freshly on a daily basis.
The Lieber-DeCarli standard liquid diet contains 35% of
energy derived from fat, 18% from protein, and 47% from
carbohydrates. The fat content of this diet is equivalent to
that found in an average normal US diet and is classiﬁed as
“healthy” by the Institute of Medicine, according to Lieber et
al., 2004 [32]. In contrast, the high-fat liquid diet contains
71% of energy derived from fat, 18% from protein, and 11%
from carbohydrates [32].
The weight of animals and their food consumption was
monitored weekly. All animals were fed the diets ad libitum
and kept with controlled temperature and humidity, under
a 12:12-hr light-dark cycle. All experiments were performed
in accordance to the guidelines of the Canadian Council on
the Care of Animals and approved by the University’s Ethics
Committee.
2.3.LiverIsolation. Overnightfastingratsunderwentlaparo-
tomy after they were anesthetized with sodium pentobarbital
(50mg/kg b.w., intraperitoneally) and the portal vein was
cannulated following the procedure described by Huet et al.,
2004 [33]. Blood was collected via the inferior vena cava
and blood glucose was directly evaluated using a commercial
glucometer (One Touch Ultra, LifeScan, Johnson & Johnson,
Milpitas, CA). Livers were ﬂushed with Krebs-Henseleit
(NaCl 0.9%, KCl 4.8mM, MgSO4 1.2mM, NaHCO3 25mM,
CaCl2 2.1mM, pH 7.4, 22◦C) buﬀer for 3 minutes then
removed and weighed. Thereafter, liver dissection was per-
formed. Pieces from the median lobe were placed in a 10%
formalin solution for histopathological analysis. Other tissue
samples were used fresh for biological determinations (see
below) or immediately frozen in liquid nitrogen then stored
at −80◦C until use.
2.4. Histology. Histological sections and hematoxylin phlox-
ine saﬀron staining (HPS) were done by the Department of
Histology of St-Justine’s Children Hospital (Montreal, QC,
Canada). Each section was scored for steatosis based on
the percentage of hepatocytes containing macrovesicular fat
and according to published criteria (grade 0: absent; grade
1: less than 33%; grade 2: 33–66%; grade 3: more than
66%) [34, 35]. Inﬂammation was expressed as the mean of
cell counts in 10 randomly selected areas (at 400x) within
each slide using the following scale (0: normal; 1: mild; 2:
m o d e r a t e ;3 :s e v e r e )[ 35]. We evaluated Mallory bodies and
collagen deposits (using HPS staining) as present or absent.
PicturesweretakenusingAxio-imagerelectronicmicroscope
(z1 Zeiss, Jena, Germany) and Axio-vision 4.2 software.
2.5. Blood Parameters. Plasma transaminases (ALT and
AST) levels, lactate dehydrogenase (LDH), triglycerides
(TG), total cholesterol (TC), low-density lipoprotein (LDL),
and high-density lipoprotein (HDL) were measured by
the Department of Biochemistry of St-Justine’s Children
Hospital (Montreal, QC, Canada). Plasma tumor necrosis
factor-α (TNF-α) was assessed using Quantikine Rat TNF-
α Immunoassay kit (R&D Systems, MN, USA). Serum
adiponectin measurements were performed using Rat
Adiponectin ELISA Kit (AdipoGen, Seoul, Korea). Plasma
insulin was evaluated with the Rat Insulin Radioimmunoas-
say (RIA) kit (Linco Research, St. Charles, MO). The home-
ostasis model assessment for insulin resistance (HOMA-IR)
index was calculated using insulin and glucose values withInternational Journal of Hepatology 3
the following formula: (fasting insulin (mU/L) × fasting
blood glucose (mmol/L)/22.5) [36].
2.6. Mitochondria Isolation. Mitochondria were isolated
from 1g of fresh liver as described by Johnson and Lardy
[37]. Brieﬂy, tissue was homogenized on ice using a Teﬂon
potter homogenizer in the isolation medium containing
sucrose (250mM), Tris-base (10mM), EGTA (1mM), and
pH 7.2 at 4◦C. To remove cellular fragments, homogenate
was centrifuged at 600g for 10min at 4◦C. Supernatant was
collected and centrifuged at 15000g for 5min at 4◦C. The
pellet was then softly washed once with the same medium,
centrifuged, and washed another time with the isolation
EGTA-free medium and centrifuged again. The ﬁnal pellet,
containing viable mitochondria, was suspended in this last
medium and stored on ice. Protein content was determined
according to the Lowry method [38].
2.7. Oxidative Stress Assessment. Liver lipid peroxidation
was determined by measuring the MDA levels, applying
the thiobarbituric acid (TBA) method, as described by
Ligeret et al. [39] with a few modiﬁcations. Brieﬂy, fresh
liver (0.5g) was homogenized on ice using a Teﬂon potter
homogenizer and a polytron in a sucrose buﬀer (4.5mL,
250mM). Homogenate was centrifuged at 2000g for 30min
at 4◦C. The supernatant was collected and protein content
was determined using the Bradford method. Supernatant
(200μL) was added to a vial containing an 8.1% (w/v)
sodium dodecyl sulfate solution, a 20% (v/v) acetic acid
solution (pH 3.5), a 0.8% (w/v) TBA solution, and distilled
water. Vials were heated at 95◦C for 45min and cooled
on ice for 2min. After butanol (4mL) was added, all vials
were mixed for 15min and centrifuged at 1000g for 10min.
Supernatants (200μL) were transferred into a 96-well plate
and thiobarbituric acid reactive substances (TBARS) were
estimated by measuring ﬂuorescence (λex = 530nm; λem =
590nm) using a multilabel counter model Wallac Victor2
(Perkin Elmer, Woodbridge, ON). The data were compared
to a standard curve of MDA (0 to 84μM) and results were
e x p r e s s e da sn m o lM D A / m go fp r o t e i n .
Lucigenin-ampliﬁed chemiluminescence was used to
determine superoxide anion in liver tissue following the
procedure described by Oliveira and colleagues [40]. Brieﬂy,
a frozen liver fragment was incubated at 37◦Cf o r1 5m i ni n
an oxygenated (95%O2-5%CO2) Krebs-HEPES buﬀer con-
taining NaCl (118.3mM), KCl (4.69mM), CaCl2 (1.87mM),
MgSO4 (1.2mM), KH2PO4 (1.03mM), NaHCO3 (25mM),
glucose (11.1mM), and Na-HEPES (20mM), pH 7.4. The
fragment was then put into a scintillation vial containing
2mL of this buﬀer, supplemented with lucigenin (250mM).
A scintillation counter (Wallac 1409 Model, Perkin Elmer
life science, St-Laurent, QC), adjusted for single-photon
emission recording mode, was used for counts appraisal
during a 15min period. Data were obtained from the area
under the counts versus time curve and expressed as a
function of the dry tissue weight (mg).
2.8. Reduced Glutathione. Fresh liver (0.5g) was minced and
homogenized on ice using a polytron in 1mL of a metaphos-
phoric acid solution (5%) prepared daily. Homogenate was
centrifuged at 3000g for 10min at 4◦C. Supernatant was
used for reduced glutathione (GSH) measurement using
the Bioxytech GSH-400 Assay Kit Oxis International inc,
Portland, OR) according to the manufacturer’s instructions.
Absorbance at 400nm was assessed using an Ultrospec 2100
pro spectrophotometer (Biochrom, Cambridge, England).
T h ed a t aw e r ec o m p a r e dt oas t a n d a r dc u rv eo fr e d u c e dG S H
(0–90μM).
2.9. Mitochondrial ATP. Freshly isolated mitochondria
(100μL) were added to ice-cold HClO4 (900μL, 1M)
[38]. Centrifugation was done at 2000g for 10min at
4◦C and supernatant (100μL) was neutralized with
KOH (47 μL, 2M) and Tris-HCl (853μL, 100mM) [39].
Measurement of bioluminescence was carried out with the
ATP Bioluminescent Assay Kit (SIGMA-Aldrich, Oakville,
ON) according to the manufacturer’s instructions using
a multilabel counter model Wallac Victor2(Perkin Elmer,
Woodbridge, ON). The data were compared to a standard
curve of ATP from 0 to 80μM and results were expressed in
μmol ATP/g of protein.
2.10. Western Blot Analysis. Western blots on total liver
homogenate were performed with a rabbit polyclonal anti-
PPAR-α primary antibody (1:400) (Santa Cruz Biotechnol-
ogy Inc. Santa Cruz, CA) similarly to procedures described
by Ouazzani-Chahdi et al. [31]. Liver microsomal fraction
was also used in western blot with mouse monoclonal anti-
rat P450 CYP2E1 antibody (1:1000) (Oxford Biomedical
Research, Oxford, MI). Secondary antibodies used are
the following: a goat polyclonal anti-rabbit (1:100000)
(Jackson Immunoresearch Laboratories, Baltimore, PA) and
a goat anti-mouse (1:4000) (Cell Signaling Technology,
Danvers, MA). Immunoreactive proteins were detected
using enhanced chemiluminescence system following the
manufacturer’s instructions GE Healthcare (ECL Western
Blotting Detection Reagents, Buckinghamshire, UK). Bands
quantiﬁcationwasachievedusingImageJ1.37v(NIH,USA).
2.11. Statistical Analysis. All results were expressed as
means ± SEM. Group means were compared by one way
ANOVA followed by Fisher’s PLSD test (and the Chi square
test for histological contingency table) using StatView 5.0.1
(SAS Institute Inc. NC). A P value < 0.05 was considered
statistically signiﬁcant.
3. Results
3.1.ChangesinBodyWeightandLiverWeight. After12weeks
of the NASH-inducing fat diet, there were no signiﬁcant dif-
ferences in body weight (BW) or weight gain (WG) between
groups. The liver weight (LW) decreased signiﬁcantly in the
N30 group compared with the NASH group (P<0.05),
similarly to the UDCA group. Furthermore, liver index
(LW/BW × 100%) increased very signiﬁcantly in the NASH4 International Journal of Hepatology
Table 1: Eﬀe c to ft r e a t m e n t so nb o d ya n dl i v e rw e i g h t .
Parameters BW (g) WG (g) LW (g) LI (%)
Control 563 ±19 475 ±81 4 .4 ±0.52 .5 ±0.1
NASH 523 ±17 464 ±15 16.2 ±0.73 .1 ±0.1∗
UDCA 505 ±15 436 ±15 13.4 ±0.6† 2.7 ±0.1†
N30 537 ±26 461 ±25 14.0 ±0.9† 2.6 ±0.1†
N15 554 ±16 478 ±17 14.6 ±0.72 .6 ±0.1†
N15+VitE 547 ±12 469 ±14 15.0 ±0.72 .7 ±0.1†
ANOVA 0.292 0.360 0.248 0.021
g r o u pa sc o m p a r e dt ot h ec o n t r o lg r o u pa n dd e c r e a s e d
signiﬁcantly in all treatment groups (P<0.05) (Table 1).
Measurements were obtained from rats on the day of
sacriﬁce, after 12 weeks of standard liquid diet (Control) or
high-fat liquid diet alone (NASH), or with treatment for the
last 6 weeks with UDCA (17.2mg/kg), NCX 1000 (30 or
15mg/kg) (N30, N15 resp.), or NCX 1000 plus vitamin E
(15mg/kg and 100mg/kg, resp.) (N15+VitE). Body weight
(BW), weight gain (WG), liver weight (LW), and liver index
(LI = LW/BW × 100%). Values are expressed as means ±
SEM of 6–10 rats. ∗P < 0.05 versus control group. †P < 0.05
versus NASH group.
3.2. Glycemic Homeostasis. Fasting glycemia in the NASH
group tended to be slightly higher than that of the control
group, but this eﬀect failed to reach statistical signiﬁcance.
However, N30 treatment signiﬁcantly lowered plasma glu-
cose as compared to the NASH group, a property similar
to that of the UDCA reference treatment (Figure 1(a),
P<0.05). In contrast, the NASH treatment caused a
frank hyperinsulinemic state as compared to the control
group (plasma insulin values of 5.56 ± 1.09 and 3.26 ±
0.31ηg/mL, resp; Figure 1(b), P<0.05). This situation was
associated with a substantial increase in insulin resistance, as
demonstrated by the signiﬁcantly greater value of HOMA-
IR in NASH animals as compared to control congeners
(Figure 1(c), P<0.05). Both plasma insulin and HOMA-IR
values were decreased signiﬁcantly by all drug intervention
groups as compared to NASH treatment (Figures 1(b) and
1(c), P<0.05). Indeed, values in N30, N15, and N15+VitE
groups were not statistically diﬀe r e n tf r o me a c ho t h e ra sw e l l
as from control animals or from UDCA reference group.
Glycemia Figure 1(a) was measured in whole blood and
insulin, Figure 1(b) was measured in plasma obtained from
rats in the fasting state, after 12 weeks of standard liquid
diet (Control), high-fat liquid diet alone (NASH), or with
treatment for the last 6 weeks with UDCA (17.2mg/kg),
NCX 1000 (30 or 15mg/kg) (N30, N15 resp.), or NCX
1000 plus vitamin E (15mg/kg + 100mg/kg) (N15+VitE).
HOMA-IR, Figure 1(c) is indicative of the insulin resistance
statefortheanimals.Valuesareexpressedasmeans ±SEMof
6–10 rats. ∗P < 0.05 versus control group. †P < 0.05 versus
NASH group.
3.3. Biochemical Parameters. Plasma transaminases (ALT,
AST) were not signiﬁcantly aﬀected by any of the treatments
(Table 2). The level of LDL rose signiﬁcantly in the NASH
group as compared with the control group (P<0.05). The
N15 treatment reduced signiﬁcantly this parameter (P<
0.05). Triglycerides were lowered by NASH induction as
compared to the control group and none of the treatments
was able to correct this parameter. In contrast, serum LDH
was highly increased by NASH treatment as compared to the
control group (P<0.05) and N30 as well as N15 treatments
succeeded in returning this parameter to control values, in
a very close manner to the UDCA treatment (P<0.05)
(Table 2).
Measurements were obtained from plasma of rats in
the fasting state, after 12 weeks of standard diet (Control)
or high-fat diet alone (NASH), or with treatment for the
last 6 weeks with UDCA (17.2mg/kg), NCX 1000 (30 or
15mg/kg) (N30, N15 resp.), or NCX 1000 plus vitamin E
(15mg/kg and 100mg/kg, respe.) (N15+VitE). AST: aspar-
tate aminotransferase; ALT: alanine aminotransferase; TC:
total cholesterol; HDL: high density lipoprotein cholesterol;
LDL: low density lipoprotein cholesterol; TG: triglycerides;
LDH: lactate dehydrogenase. Values are expressed as means
± SEM of 6–10 rats. The P values for the ANOVA Fisher’s
PLSD test are given. For pairwise comparisons ∗P < 0.05
versus control group and †P < 0.05 versus NASH group.
3.4. Histological Evaluation. Liver histology is currently the
gold standard test for the diagnosis of NASH. HPS staining
o fl i v e rs e c t i o n sf r o mr a t si nt h ec o n t r o lg r o u p( Figure 2(a))
showed normal morphological features. The tissues of all
animals from the NASH group (Figure 2(b)) were found to
exhibit macrovesicular steatosis of grade 2 or 3 conﬁrming
that more than a third of hepatocytes contained macrovesic-
ular fat (Table 3; P<0.05 Chi square test). Moreover, Mallory
bodies (Figure 2(c)) and collagen deposition (Figure 2(d))
were encountered exclusively in a number of samples from
the NASH group. All treatments yielded statistically signif-
icant improvements in histology. As compared to NASH
animals, 60 to 70% of rats in groups treated with N30,
N15, or NCX 1000 combined with vitamin E had less than
a third of hepatocytes containing macrovesicular fat, in
the same way as the UDCA treated rats (Figures 2(e) to
2(h); Table 3, P<0.05 Chi square test). The inﬁltration of
inﬂammatory cells in hepatic tissue was very seldom seen in
controlanimals.Incontrast,100%ofNASHanimalssuﬀered
from moderate to severe inﬂammatory cell inﬁltration, a
signiﬁcant change from control animals (Table 3, P<0.05
Chi square test). N30 treatment signiﬁcantly improved this
parameter, similarly to UDCA treatment (Table 3, P<0.05
Chi square test). Reducing the dose of NCX 1000 with or
without combination with vitamin E also yielded a slightly
inferior yet signiﬁcant beneﬁcial eﬀect.
Histological scoring for steatosis and inﬂammation from
rats fed a standard liquid diet for 12 weeks (Control) or a
high-fat liquid diet alone (NASH), or with treatment for the
last 6 weeks with UDCA (17.2mg/kg), NCX 1000 (30 or
15mg/kg) (N30, N15 resp.), or NCX 1000 plus vitamin E
(15mg/kg and 100mg/kg, resp.) (N15+VitE). Macrovesic-
ular steatosis grade 0: absent; grade 1: less than 33%; grade 2:International Journal of Hepatology 5
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Figure 1: Eﬀect of treatments on glycemic homeostasis.
Table 2: Eﬀect of treatments on biochemical and lipid parameters.
Parameters AST ALT TC HDL LDL TG LDH
U/L U/L mmol/L mmol/L mmol/L mmol/L U/L
Control 53.5 ±4.93 0 .2 ±3.60 .75 ±0.07 0.37 ±0.03 0.09 ±0.04 0.72 ±0.02 62 ±5
NASH 67.8 ±9.53 9 .8 ±5.60 .82 ±0.02 0.35 ±0.05 0.25 ±0.03∗ 0.31 ±0.04∗ 111 ±13∗
UDCA 59.2 ±2.53 4 .2 ±2.40 .54 ±0.03† 0.27 ±0.01 0.17 ±0.02 0.29 ±0.03∗ 68 ±4†
N30 54.2 ±5.83 1 .7 ±4.50 .75 ±0.06 0.38 ±0.03 0.21 ±0.03 0.35 ±0.03∗ 68 ±8†
N15 57.9 ±5.73 6 .5 ±4.90 .64 ±0.05 0.32 ±0.03 0.14 ±0.02† 0.31 ±0.02∗ 77 ±12†
N15+VitE 51.7 ±3.92 9 .1 ±2.70 .70 ±0.06 0.29 ±0.03 0.23 ±0.04 0.36 ±0.03∗ 80 ±13
ANOVA 0.448 0.461 0.033 0.053 0.012 <0.0001 0.077
33–66%; grade 3: more than 66%. Inﬂammation 0: normal;
1: mild; 2: moderate; 3: severe.
Representative HPS staining of rat liver sections. The
control (A-CTL, 20X) group received 12 weeks of standard
liquid diet and showed normal histology. The NASH (B, C,
D-NASH, 20X, and 63X) group received a high-fat liquid
diet during 12 weeks and revealed macrovesicles of fat,
hepatocyte ballooning, inﬂammatory cells inﬁltration such
as monocytes (M) and neutrophils (N), necrosis (Nec), and
Mallory bodies (Mallory). 12 weeks of high-fat liquid diet
with treatment during the last 6 weeks with either UDCA
17.2mg/kg (E-UDCA, 20X), NCX 1000 30 or 15mg/kg (F-
N30 and G-N15, resp; 20X), or NCX 1000 15mg/kg plus
vitamin E 100mg/kg (H-N15+VitE, 20X), displayed less
macrovesicular steatosis and inﬂammation than the NASH
group.6 International Journal of Hepatology
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Figure 2: Eﬀect of treatments on liver histology.
3.5. Inﬂammatory Cytokines and Adipokines. TNF-α is an
inﬂammatory cytokine produced by adipose tissue and
macrophages (including liver Kupﬀer cells). It is known
to impair insulin signaling, leading eventually to insulin
resistance. In the NASH group, plasma TNF-α was higher
than in the control group (Figure 3(a);3 6 .3 ± 9.3v e r s u s
13.5 ± 6.4ρg/mL, resp.; P<0.05). All drug treatments
diminished circulating TNF-α level signiﬁcantly, in a similarInternational Journal of Hepatology 7
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Figure 3: Eﬀect of treatments on inﬂammatory cytokines and adipokines.
Table 3: Liver histology scoring for macrovesicular steatosis and
inﬂammatory cells inﬁltration.
Groups
n
Steatosis Inﬂammation
0123 0123
C o n t r o l 6 6000 6000
N A S H 6 0024 0042
U D C A 1 0 3331 3430
N 3 0 1 0 2521 3430
N 1 5 1 0 5212 3421
N 1 5 + V i t E 1 0 3322 4321
Chi square P<0.05 P<0.05
and dose-dependent manner (N30, N15) or more eﬀective
manner(N15+VitE)thanUDCA,ascomparedtotheNASH
group (P<0.05). Adiponectin is a hormone secreted by
adipose tissue that is known to decrease during fatty liver
disease and the metabolic syndrome. Indeed, the high-fat
NASH treatment induced a signiﬁcant reduction in serum
adiponectin as compared to the control group (Figure 3(b);
P<0.05). All drug treatments, notably the N30 group, had
a tendency to increase circulating adiponectin but this eﬀect
failed to reach statistical analysis.
TNF-α Figure 3(a) and adiponectin Figure 3(b) were
measured using ELISA kits in plasma and serum, respec-
tively, and were obtained from rats in the fasting state,
after 12 weeks of standard liquid diet (Control), high-fat
liquid diet alone (NASH), or with treatment for the last 6
weekswithUDCA(17.2mg/kg),NCX1000(30or15mg/kg)
(N30, N15 resp.), or NCX 1000 plus vitamin E (15mg/kg +
100mg/kg) (N15+VitE). Values are expressed as means ±
SEM of 6–10 rats. ∗P < 0.05 versus control group. †P < 0.05
versus NASH group.
3.6. Oxidative Stress. Twelve weeks of the NASH-inducing
high-fat diet caused hepatic malondialdehyde (MDA) levels,
a product of lipid peroxidation, to more than quadruple as
compared to the control group (4.87 ± 1.03 versus 0.74 ±
0.08ηmol/mg of protein, resp; P<0.05, Figure 4(a)).
N30 treatment during the last six weeks normalized liver
M D Al e v e l si na ne q u i v a l e n tw a yt oU D C Ab u ti nab e t t e r
way than N15, suggesting a dose-eﬀect relationship. When
v i t a m i nEw a sc o m b i n e dw i t hN 1 5 ,M D Al e v e l sd e c r e a s e dt o
levels slightly below those of the control group, suggesting a
possible additive eﬀect.
The superoxide anion (O2
•−), an important reactive
oxygen species (ROS), is produced by the liver during
oxidative stress. Figure 4(b) shows that the level of hepatic
O2
•− exhibited a near twofold increase in the NASH group
as compared to the control group (4,506 ± 440 and 2,186 ±
183AUC/mg dry tissue, resp.; P<0.05). All treatments,
notably N30 and N15 + VitE, decreased O2
•− levels signif-
icantly, to values similar to that of UDCA reference group.
Hepatic-reduced glutathione (GSH) is a potent antioxi-
dant produced by the liver as a mechanism of intracellular
defense. As illustrated by Figure 4(c), GSH level was signif-
icantly elevated in the NASH group when compared with
the control group (17.4 ± 0.6v e r s u s1 0 .0 ± 0.4mmol/g of
protein, P<0.05). These results are demonstrative of the
stress induced by a 12-week high-fat liquid diet. Again, N30,
N15+VitE, and N15 treatments, in order of importance,
returned hepatic glutathione to levels similar to that of the
control and UDCA groups (P<0.05).
Hepatic malondialdehyde (MDA) Figure 4(a),O 2
•− pro-
duction Figure 4(b), and GSH concentration Figure 4(c)
were measured in fresh or frozen liver tissue obtained from
rats in the fasting state, after 12 weeks of standard liquid
diet (Control), high-fat liquid diet alone (NASH), or with
treatment for the last 6 weeks with UDCA (17.2mg/kg),
NCX 1000 (30 or 15mg/kg) (N30, N15 resp.), or NCX 1000
plus vitamin E (15mg/kg + 100mg/kg) (N15+VitE). Values
a r ee x p r e s s e da sm e a n s± SEM of 6–10 rats.
∗P < 0.05 versus
control group.
†P < 0.05 versus NASH group.
3.7. Mitochondrial ATP. As shown in Figure 5,h e p a t i c
mitochondrial ATP level was lower in the NASH group8 International Journal of Hepatology
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Figure 4: Eﬀect of treatments on oxidative stress.
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Figure 5: Eﬀect of treatments on mitochondrial ATP.
than in the control group (P<0.05). This is indicative of
cellular energetic imbalance caused by a 12-week high-fat
liquiddiet.AlldrugtreatmentgroupsyieldedATPvaluesthat
were statistically similar to both the UDCA and the control
groups.
ATP was measured in freshly isolated mitochondria
obtained from rats in the fasting state, after 12 weeks of
standard liquid diet (Control), high-fat liquid diet alone
(NASH), or with treatment for the last 6 weeks with
UDCA (17.2mg/kg), NCX 1000 (30 or 15mg/kg) (N30, N15
resp.), or NCX 1000 plus vitamin E (15mg/kg+100mg/kg)
( N 1 5+V i t E ) .V a l u e sa r ee x p r e s s e da sm e a n s± SEM of 6–10
rats. Overall ANOVA was not signiﬁcant among all groups.
Nonetheless, single t-test revealed signiﬁcance for NASH
versus control group ∗P < 0.05.
3.8. Expression of CYP2E1 and PPAR-α. The expression
of the metabolizing enzyme cytochrome P450 CYP2E1 is
upregulated by the overproduction of ketones, which is due
to impaired mitochondrial β-oxidation as well as increased
peroxisomalβ-oxidationandmicrosomalω-oxidationoffree
fatty acids (FFAs) in hepatocytes. Western blots showed that
the microsomal expression of cytochrome P450 CYP2E1 wasInternational Journal of Hepatology 9
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Figure 6: Eﬀect of treatments on CYP2E1 and PPAR-α.
increased after 12 weeks of high-fat liquid diet in livers
from the NASH group (98% above control, P<0.05).
CYP2E1 expression in the drug treatment groups, except in
that of N15+VitE, was lowered to values close to those of
the control group, but this diﬀerence was not statistically
signiﬁcant from the NASH group (Figure 6(a)).
The expression of peroxisome proliferator-activated
receptor-α (PPAR-α), a transcription factor responsible for
the activation of fat metabolism genes, was signiﬁcantly
decreased in the livers of NASH animals as compared to
values observed in the control group (33% of control, P<
0.05), but was not aﬀected signiﬁcantly by any treatment in
our study when compared to the NASH group as shown by
the representative western blots (Figure 6(b)).
Representative western blots were performed on liver
microsomal fraction for CYP2E1 Figure 6(a) or whole liver
homogenates for PPAR-α Figure 6(b) to reveal their protein
expression. Livers were obtained from rats in the fasting
state, after 12 weeks of standard liquid diet (CTL), high-fat
liquid diet alone (NASH), or with treatment for the last 6
weekswithUDCA(17.2mg/kg),NCX1000(30or15mg/kg)
(N30, N15 resp.), or NCX 1000 plus vitamin E (15mg/kg +
100mg/kg) (N15+VitE). Values are expressed as means ±
SEM of 4 samples.
∗P < 0.05 versus control group.10 International Journal of Hepatology
4. Discussion
NASH is a threatening liver disease that can progress
through ﬁbrosis and cirrhosis. It has been associated with
the metabolic syndrome and its incidence is thus following a
similar expanding trend, reaching 3% of worldwide popula-
tions[2,41].Atpresent,noeﬃcientremedyexists.Treatment
is still centered on major lifestyle changes (weight loss,
healthy eating, and exercise) [42], with emerging therapeutic
avenues focused on improving insulin resistance, reducing
inﬂammation as well as oxidative stress [43, 44]. In the
search for potential novel and beneﬁcial treatment options,
NCX 1000 has attracted our attention. Indeed, this substance
exerts a wide spectrum of beneﬁcial eﬀects in the liver [25–
30].WethereforeevaluatedthebeneﬁcialeﬀectofNCX1000,
combined or not to vitamin E, in an experimental in vivo rat
model of NASH and used UDCA, its parent molecule, as a
reference treatment.
We selected a NASH rat model developed by Lieber and
colleagues, that is based on the consumption of a high-
fat liquid diet [32]. Our results conﬁrmed that a 12-week
treatment with a high-fat liquid diet triggered all the salient
features of NASH in rats and reproduced the majority of
the clinical expressions of the human disease. Furthermore,
in preliminary studies, the cardinal histological features of
NASH (steatosis, inﬂammation and ﬁbrosis) were already
present after six weeks of the Lieber diet, in accordance with
the original description of the model [32]. We therefore
began treatments at that time point, with the intention of
treating the disease.
Our results showed that N30 treatment for six weeks was
very eﬃcient at reversing the development of NASH, despite
the continued intake of the high-fat liquid diet. Indeed,
the cardinal features of NASH were eﬀectively antagonized.
Firstly, the histological grade of steatosis was dramatically
improved. NCX 1000 treatment at a dose of 30mg/kg was
also eﬃcient at correcting NASH-associated inﬂammation,
as seen by the signiﬁcant histological improvement in
immune cell inﬁltration and by the reduction in circulating
TNF-α. Histological evidence of necrosis or ﬁbrosis was
also not observed in the livers of N30 animals, as opposed
to NASH congeners. Finally, N30 treatment successfully
normalized all measured parameters of hepatic oxidative
stress (lipid peroxidation, ROS production, and glutathione
content). This was consistent with the return of circulating
LDH towards normal values observed in control animals.
Such antioxidant, cytoprotective, and antiﬁbrogenic eﬀects
of NCX 1000 are in line with previous reports [26, 29],
including our own studies using an amiodarone-induced
NASH-like in vitro model [31]. In addition, microsomal
CYP2E1 expression tended to decrease in NCX 1000 treated
animals,inlinewiththeimprovementofoxidative stress,but
such normalization failed to reach statistical signiﬁcance. A
correlation was recently established between the expression
of other members of the cytochrome P450 enzymes, TNF-
α, and the progression of NAFLD [45]. Further investigation
will be necessary to assess the eﬀects of our treatments on
these other isoforms of cytochrome P450.
NCX 1000 also restored several metabolic parameters
associated with NASH. This was notably the case with
indices of insulin resistance, as attested by the normalization
of insulinemia and of HOMA-IR. This is not surpris-
ing given the known relation between liver steatosis and
the development of insulin resistance [10]; the reduction
in steatosis induced by NCX 1000 thus contributing to
improve insulin sensitivity. Together with the decrease in
plasma TNF-α already mentioned, the tendency for serum
adiponectin levels to rise back toward normal control values
may also have contributed in restoring insulin sensitivity
in N30 animals [5, 19, 46, 47]. However, perturbations in
blood lipids, notably increased LDL and decreased PPAR-α
expression, observed in NASH animals were not corrected by
N30 treatment.
The treatment with a lower dose of NCX 1000 (N15)
seemed to be less eﬃcient than N30, notably in terms of
L D Hr e l e a s e ,M D A ,a n dO 2
•− production, suggesting a dose-
dependent eﬀect more speciﬁcally at the level of oxidative
stress parameters. Indeed, for all other parameters, N15 had
very similar eﬀects to those of N30.
We also assessed the combination of NCX 1000 with
natural antioxidants, in a rationale to diminish the dose
of the chemical drug, hence to reduce the risk of possible
adverse reactions. Vitamin E (α-tocopherol) is a lipophilic
antioxidant widely known for its beneﬁcial eﬀects on
NAFLD.Infact,itreduceslipidperoxidation,improvesﬁbro-
sis, attenuates inﬂammation, and stabilizes membranes due
to its lipid solubility [48, 49]. It has already been combined
with UDCA in a small-scale clinical study for the treatment
of NASH and improved liver steatosis and transaminase
levels as compared to UDCA with placebo [19, 22]. We also
recently showed that vitamin E, as opposed to hydrophilic
antioxidants, signiﬁcantly enhanced the antioxidant and
cytoprotectivepotentialofNCX1000inculturedhepatocytes
with NASH-like lesions [31]. Results from the present study
show that the association of vitamin E with N15 signiﬁcantly
enhanced the beneﬁcial eﬀects of NCX 1000 against NASH-
induced lesions. This was especially true at the level of
lipid peroxidation and superoxide anion production. Thus,
it appears that vitamin E can oﬀer an additional antioxidant
protectionthatmaysynergizewithlowerdosesofNCX1000.
This is consistent with the concept that vitamin E’s main
target in experimental NASH is oxidative stress.
Overall, our results thus clearly demonstrate that NCX
1000 holds a promising potential for the treatment of NASH
and suggest that the dose can be lowered if the drug is
combined with vitamin E. Further studies will be needed
to characterize precisely the ratio between NCX 1000 and
vitamin E needed to obtain the maximum eﬀect with the
lower doses.
Finally, NCX 1000 exerted antioxidant, anti-inﬂamma-
tory, cytoprotective, and insulin sensitizing activities as efﬁ-
cient as UDCA, at a clinically relevant dose of 17.2mg/kg. In
the liver, NCX 1000 is expected to be metabolized to release
NO and an equimolar amount of UDCA. The higher N30
dose used in this study should therefore theoretically have
provided an equivalent amount to the UDCA dose tested.
Since the eﬀects of NCX 1000 and UDCA were comparable,International Journal of Hepatology 11
our study would argue for a minimal role of NO in the
observed beneﬁcial action in NASH. This conclusion diﬀers
from our previous in vitro study [31], where equimolar
NCX 1000 aﬀorded better protection than UDCA to mouse
hepatocytes treated with amiodarone to produce NASH-like
injuries. Further studies will thus be necessary to fully assess
theroleoftheNOinthecurrentmodel.NCX1000atalower
dose, combined with vitamin E, did aﬀord an advantage by
reducing the corresponding dose of UDCA required. Future
studiesshouldthereforealsocompareNCX1000andUDCA,
each combined with vitamin E to fully assess if NCX 1000
oﬀers any advantage over the parent compound.
In conclusion, our study demonstrates for the ﬁrst time
that a therapeutic treatment with NCX 1000 is eﬀective
in reducing steatosis, inﬂammation, oxidative stress, and
insulin resistance in an in vivo rat model of diet-induced
NASH.Inthismodel,NCX1000 does notappeartooﬀerany
advantage over equimolar amounts of the parent compound
UDCA.However,theresultsofourstudyalsosupporttheuse
of combinations of lower doses of NCX 1000 with natural
lipophilic antioxidants, such as vitamin E, as a valid option
for the treatment of NASH. A clinical validation of this
approach will remain mandatory.
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